The DOI matches its Crossref record, with a small difference in title or year; 36 of the 36 references it cites were found in a registry or an index.
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Abstract
Background—: Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients with diabetes mellitus. We sought to describe cardiovascular outcomes at 4 years and to identify predictors of these events in patients with diabetes mellitus. Methods and Results—: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients at high risk of atherothrombosis or established atherothrombosis. Four-year event rates in patients with diabetes mellitus were determined with the corrected group prognosis method. Of the 45 227 patients in the REACH registry who had follow-up at 4 years, 43.6% (n=19 699) had diabetes mellitus at baseline. The overall risk and hazard ratio (HR) of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke were greater in patients with diabetes compared with patients without diabetes (16.5% versus 13.1%; adjusted HR, 1.27; 95% confidence interval [CI] 1.19–1.35). There was also an increase in both cardiovascular death (8.9% versus 6.0%; adjusted HR, 1.38; 95% CI, 1.26–1.52) and overall death (14.3% versus 9.9%; adjusted HR, 1.40; 95% CI, 1.30–1.51). Diabetes mellitus was associated with a 33% greater risk of hospitalization for heart failure (9.4% versus 5.9%; adjusted odds ratio, 1.33; 95% CI, 1.18–1.50). In patients with diabetes mellitus, heart failure at baseline was independently associated with cardiovascular death (adjusted HR, 2.45; 95% CI, 2.17–2.77; P <0.001) and hospitalization for heart failure (adjusted odds ratio, 4.72; 95% CI, 4.22–5.29; P <0.001). Conclusions—: Diabetes mellitus substantially increases the risk of death, ischemic events, and heart failure. Patients with both diabetes mellitus and heart failure are at particularly elevated risk of cardiovascular death, highlighting the need for additional therapies in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [4]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [53]
In the citing paper
“Recent studies have found that rates of incident heart failure hospitalization (adjusted for age and sex) were twofold higher in people with diabetes compared with those without (5,6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1001/jama.1988.03410230074031 · DOI
Cited by
Sorted by citations
Items 101–200 of 500
Correlation Between Glycemic Variability and Diabetic Complications: A Narrative Review
Huang, L., Pan, Y., Zhou, K., Liu, H., & Zhong, S. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s418520 · Cited by 54
Sharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z. J., Hudson, L. L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 56
Feng, L., Gu, C., Li, Y., & Huang, J. (2017) · BioMed Research International · doi:10.1155/2017/1414070 · Cited by 52
Hu, P., Lei, Q., Duan, S., Fu, Y., Pan, H., Chang, C., Zheng, Z., Wu, Y., Zhang, Z., Li, R., et al. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212773 · Cited by 50
Choi, Y. S., & Choi, J. W. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01032-5 · Cited by 52
Khan, M. S., Felker, G. M., Piña, I. L., Camacho, A., Bapat, D., Ibrahim, N. E., Maisel, A. S., PRESCOTT, M. F., Ward, J. H., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.09.014 · Cited by 50
Christensen, R. H., von Scholten, B. J., Hansen, C. S., Heywood, S. E., Rosenmeier, J. B., Andersen, U. B., Hovind, P. H., Reinhard, H., Parving, H., Pedersen, B. K., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717820 · Cited by 48
Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs
Mačvanin, M., Gluvic, Z. M., Radovanović, J., Essack, M., Gao, X., & Isenović, E. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124613 · Cited by 47
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Scirica, B. M. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255539 · Cited by 47
Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland
Si, Y., Wang, C., Guo, Y., Yin, H., & Ma, Y. (2020) · Medicine · doi:10.1097/md.0000000000019762 · Cited by 46
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 47
Targher, G., Dauriz, M., Tavazzi, L., Temporelli, P. L., Lucci, D., Urso, R., Lecchi, G., Bellanti, G., Merlo, M., Rossi, A., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.207 · Cited by 45
Schwab, U., Reynolds, A. N., Sallinen, T., Rivellese, A. A., & Risérus, U. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02507-1 · Cited by 45
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 43
Branch, K. R. H., Dagenais, G. R., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Jansky, P., Lakshmanan, M., Lanas, F., Leiter, L. A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2670 · Cited by 41
Win, T. T., Davis, H. T., & Laskey, W. K. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.003023 · Cited by 43
Divakaran, S., Singh, A., Biery, D. W., Yang, J., DeFilippis, E. M., Collins, B., Ramsis, M., Qamar, A., Hainer, J. M., Klein, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0998 · Cited by 44
Self-citationSharma, A., Vaduganathan, M., Ferreira, J. P., Liu, Y., Bakris, G. L., Cannon, C. P., White, W. B., & Zannad, F. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012797 · Cited by 40
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Self-citationMicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 44
The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
Cianciolo, G., Pascalis, A. D., Gasperoni, L., Tondolo, F., Zappulo, F., Capelli, I., Cappuccilli, M. L., & Manna, G. L. (2020) · Molecules · doi:10.3390/molecules25122757 · Cited by 42
A population-based study of causes of death after endometrial cancer according to major risk factors
Lees, B. F., Hampton, J. M., Trentham‐Dietz, A., Newcomb, P. A., & Spencer, R. J. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.12.020 · Cited by 42
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes
Thomas, M. C. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154961 · Cited by 41
Kondo, K., Yanishi, K., Hayashida, R., Shintani, S., Shibata, R., Murotani, K., Ando, M., Mizuno, M., Fujiwara, T., Murohara, T., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-0510 · Cited by 41
Gorski, D. J., Petz, A., Reichert, C., Twarock, S., Grandoch, M., & Fischer, J. W. (2019) · Scientific Reports · doi:10.1038/s41598-018-36140-6 · Cited by 40
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention
Abovich, A., Matasic, D. S., Cardoso, R. N., Ndumele, C. E., Blumenthal, R. S., Blankstein, R., & Gulati, M. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100527 · Cited by 44
Walker, A. M., Patel, P. A., Rajwani, A., Groves, D., Denby, C. E., Kearney, L. C., Sapsford, R. J., Witte, K. K., Kearney, M. T., & Cubbon, R. M. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116653342 · Cited by 40
Mak, K.-H., Vidal-Petiot, E., Young, R., Sorbets, E., Greenlaw, N., Ford, I., Tendera, M., Ferrari, R., Tardif, J.-C., Udell, J. A., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab011 · Cited by 39
Self-citationImpaired fasting glucose: a risk factor for atrial fibrillation and heart failure
Lind, V., Hammar, N., Lundman, P., Friberg, L., Talbäck, M., Walldius, G., & Norhammar, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01422-3 · Cited by 43
Tsujimoto, T., & Kajio, H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11408 · Cited by 38
Segar, M. W., Patel, K. V., Hellkamp, A. S., Vaduganathan, M., Lokhnygina, Y. V., Green, J. B., Wan, S., Kolkailah, A. A., Holman, R. R., Peterson, E. D., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024094 · Cited by 38
Dong, X., Li, N., Zhu, C., Wang, Y., Shi, K., Pan, H. B., Wang, S., Shi, Z., Geng, Y., Wang, W., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01748-0 · Cited by 37
Gallwitz, B. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 36
Gulizia, M. M., Colivicchi, F., Abrignani, M. G., Ambrosetti, M., Aspromonte, N., Barile, G., Caporale, R., Casolo, G., Chiuini, E., Lenarda, A. D., et al. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy019 · Cited by 38
Adiponectin Modified BMSCs Alleviate Heart Fibrosis via Inhibition TGF-beta1/Smad in Diabetic Rats
Meng, K., Cai, H., Huang, Q., Hong, Y., & Zhang, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.2139/ssrn.3748363 · Cited by 36
Sharma, A., Al‐Khatib, S. M., Ezekowitz, J. A., Cooper, L. B., Fordyce, C. B., Felker, G. M., Bardy, G. H., Poole, J. E., Bigger, J. T., Buxton, A. E., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1192 · Cited by 35
Arnold, S. V., Echouffo-Tcheugui, J. B., Lam, C. S. P., Inzucchi, S. E., Tang, F., McGuire, D. K., Goyal, A., Maddox, T. M., Sperling, L. S., Fonarow, G. C., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.05.016 · Cited by 35
Berezin, A. Е., & Berezin, A. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00835-9 · Cited by 34
Taggart, D. P., Audisio, K., Gerry, S., Robinson, N. B., Rahouma, M., Soletti, G. J., Cancelli, G., Benedetto, U., Lees, B., Gray, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac199 · Cited by 33
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Poor Glycemic Control Is Associated With Increased Extracellular Volume Fraction in Diabetes
AlBadri, A., Hashmath, Z., Oldland, G., Miller, R., Javaid, K., Syed, A. A., Ansari, B. A., Gaddam, S., Witschey, W. R. T., Akers, S. R., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0324 · Cited by 33
McAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period
Świątkiewicz, I., Magielski, P., & Kubica, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063169 · Cited by 34
Outcomes of Participants With Diabetes in the ISCHEMIA Trials
Newman, J. D., Anthopolos, R., Mancini, G. B. J., Bangalore, S., Reynolds, H. R., Kunichoff, D. F., Senior, R., Peteiro, J., Bhargava, B., Garg, P., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054439 · Cited by 34
North, E. J., & Newman, J. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000673 · Cited by 34
Mina, G. S., Gill, P., Soliman, D., Reddy, P. C., & Dominic, P. S. (2017) · Clinical Cardiology · doi:10.1002/clc.22723 · Cited by 31
Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis
Luo, X., Yan, C., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.004 · Cited by 35
Rea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 32
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
Bergmark, B. A., Bhatt, D. L., Braunwald, E., Morrow, D. A., Steg, P. G., Gurmu, Y., Cahn, A., Mosenzon, O., Raz, I., Bohula, E. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1736 · Cited by 33
Self-citationBraga, J. R., Tu, J. V., Austin, P. C., Sutradhar, R., Ross, H. J., & Lee, D. S. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx015 · Cited by 31
Singh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 31
Yaribeygi, H., Lhaf, F., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.013 · Cited by 34
SGLT2 inhibitors, sodium and off-target effects: an overview
Pascalis, A. D., Cianciolo, G., Capelli, I., Brunori, G., & Manna, G. L. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00845-7 · Cited by 31
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Heart failure event definitions in drug trials in patients with type 2 diabetes
Sharma, A., Bhatt, D. L., Calvo, G., Brown, N. J., Zannad, F. M., & Mentz, R. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00049-8 · Cited by 30
Self-citationAssociation of diabetes with frequency and cost of hospital admissions: a retrospective cohort study
Choi, J. A., Booth, G. L., Jung, H. Y., Lapointe‐Shaw, L., Tang, T., Kwan, J. L., Rawal, S., Weinerman, A. S., Verma, A. A., & Razak, F. A. (2021) · CMAJ Open · doi:10.9778/cmajo.20190213 · Cited by 30
Li, Y., Tsai, S., Chen, D., Chen, S., Sun, J., Chang, H., Liou, M., & Chen, T. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0655-y · Cited by 30
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 29
Faconti, L., Mills, C. E., Govoni, V., Gu, H., Morant, S. V., Jiang, B., Cruickshank, J. K., & Webb, A. J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13783 · Cited by 30
Verma, S., Anker, S. D., Butler, J., & Bhatt, D. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13148 · Cited by 30
Self-citationKhalil, C. A., Sulaiman, K., Singh, R., Jayyousi, A., Asaad, N., AlHabib, K. F., Alsheikh-Ali, A. A. A., Al‐Jarallah, M., Bulbanat, B., Almahmeed, W. A., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.119 · Cited by 28
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Jung, C., & Mok, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.260 · Cited by 28
Elevated exhaled acetone concentration in stage C heart failure patients with diabetes mellitus
Yokokawa, T., Sato, T., Suzuki, S., Oikawa, M., Yoshihisa, A., Kobayashi, A., Yamaki, T., Kunii, H., Nakazato, K., Suzuki, H., et al. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0713-0 · Cited by 27
Bhatt, D. L., Fox, K. M., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., Andersson, M., Himmelmänn, A., Ridderstråle, W., Held, C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23164 · Cited by 25
Self-citationCongestive heart failure caused by silent ischemia and silent myocardial infarction
Valensi, P. E., & Meune, C. (2019) · Herz · doi:10.1007/s00059-019-4798-3 · Cited by 32
Elharram, M., Ferreira, J. P., Huynh, T. T., Ni, J., Giannetti, N., Verma, S., Zannad, F. M., & Sharma, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14283 · Cited by 26
From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
Poznyak, A. V., Litvinova, L. S., Poggio, P., Moschetta, D., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179738 · Cited by 27
SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad113 · Cited by 27
del Val, D., Berta, B., Roleder, T., Malinowski, K. P., Bastante, T., Hermanides, R. S., Wojakowski, W., Fabris, E., Cuesta, J., Luca, G. D., et al. (2024) · EuroIntervention · doi:10.4244/eij-d-23-00628 · Cited by 24
Real, J., Vlacho, B., Ortega, E., Vallés, J. A., Mata‐Cases, M., Castelblanco, E., Wittbrodt, E. T., Fenici, P., Kosiborod, M., Mauricio, D., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01323-5 · Cited by 26
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 31
Liu, M., Peng, T., Hu, L., Wang, M., Guo, D. S., Qi, B., Ren, G., Wang, D., Li, Y., Song, L., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.77469 · Cited by 25
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Brito, D. A., Bettencourt, P., Carvalho, D. M., Ferreira, J., Fontes‐Carvalho, R., Franco, F., Moura, B., Silva‐Cardoso, J., de Melo, R. T., & Fonseca, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06973-3 · Cited by 24
Vijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 24
O'Leary, C. P., & Cavender, M. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13948 · Cited by 23
Self-citationPatel, P. A., Liang, L., Khazanie, P., Hammill, B. G., Fonarow, G. C., Yancy, C. W., Bhatt, D. L., Curtis, L. H., & Hernandez, A. F. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002638 · Cited by 23
Self-citationClinical Phenogroups in Heart Failure with Preserved Ejection Fraction
Sorimachi, H., Omote, K., & Borlaug, B. A. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.009 · Cited by 24
Turgut, Ö., Müller, P., Hager, P., Shit, S., Starck, S., Menten, M. J., Martens, E., & Rueckert, D. (2025) · Medical Image Analysis · doi:10.1016/j.media.2024.103451 · Cited by 22
Husaini, B. A., Levine, R. S., Norris, K. C., Cain, V. A., Bazargan, M., & Moonis, M. (2016) · Ethnicity & Disease · doi:10.18865/ed.26.3.345 · Cited by 22
Oikonomou, E. K., Mourouzis, K., Fountoulakis, P. N., Papamikroulis, G.-A., Siasos, G., Antonopoulos, A. S., Vogiatzi, G., Tsalamadris, S., Vavuranakis, M., & Tousoulis, D. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9682-3 · Cited by 22
Predictors of heart failure development in type 2 diabetes
Verma, S., Sharma, A., Kanumilli, N., & Butler, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000647 · Cited by 22
New Decade, New FDA Guidance for Diabetes Drug Development
Ferro, E. G., Michos, E. D., Bhatt, D. L., Lincoff, A. M., & Elshazly, M. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.590 · Cited by 22
Self-citationThe burden of heart failure in the general population: a clearer and more concerning picture
von Lueder, T. G., & Agewall, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.153 · Cited by 21
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 24
Ziaeian, B., Hernandez, A. F., DeVore, A. D., Wu, J., Xu, H., Heidenreich, P. A., Matsouaka, R., Bhatt, D. L., Yancy, C. W., & Fonarow, G. C. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.006 · Cited by 21
Self-citationFerrini, M., Johansson, I., & Aboyans, V. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885461 · Cited by 21
Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 24
Główczyńska, R., Piotrowicz, E., Szalewska, D., Piotrowicz, R., Kowalik, I., Pencina, M. J., Zaręba, W., Banach, M., Orzechowski, P., Pluta, S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01292-9 · Cited by 22
Gray, K. D., Moore, M. D., Bellorín, O., Abelson, J. S., Dakin, G. F., Zarnegar, R., Pomp, A., & Afaneh, C. I. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2904-2 · Cited by 21
Santamarina, M. L., & Carlson, C. J. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1036-0 · Cited by 20
Kato, E. T., & Kimura, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0013 · Cited by 21
Feng, W., Li, Z., Guo, W., Fan, X., Zhou, F., Zhang, K., Ou, C., Huang, F., & Chen, M. (2020) · Diabetes Care · doi:10.2337/dc20-0838 · Cited by 19
How Diabetes and Heart Failure Modulate Each Other and Condition Management
Randhawa, V. K., Dhanvantari, S., & Connelly, K. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.014 · Cited by 20
Leiter, L. A., Bhatt, D. L., McGuire, D. K., Teoh, H., Fox, K. M., Simon, T., Mehta, S. R., Lev, E. I., Kiss, R. G., Dalby, A. J., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.298 · Cited by 21
Self-citationRichardson, T. L., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Griffin, M. R., Elasy, T. A., & Roumie, C. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019211 · Cited by 19
Arthur, R., Møller, H., Garmo, H., Häggström, C., Holmberg, L., Stattin, P. E., Malmström, H., Lambe, M. P., Hammar, N., Walldius, G., et al. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1093-1 · Cited by 19
Chen, H.-M., Yang, Y., Chen, K.-J., Lee, Y. L., McIntyre, R. S., Lu, M., Lee, Y.-C., Hsieh, M.-C., & Chen, V. C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02362 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Metadata
- Authors
- Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- From TIMI Study Group, Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.A.C., J.K., K.I., D.L.B.); French Alliance for Cardiovascular Clinical Trials, Département Hospitalo-Universitaire, Fibrosis, Inflammation, Remodeling, Université Paris-Diderot, Sorbonne Paris-Cité, Laboratory of Vascular Translational Science, INSERM U-1148, Hôpital Bichat, Hopitaux Universitaires Paris-Nord Val de Seine, Assistance Publique–Hôpitaux de Paris, Paris, France (P.G.S.);...
- ORCID
- Venue
- Circulation
- Published
- 2015-09-08
- Volume
- 132
- Issue
- 10
- Pages
- 923-931
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2154038775
- Cited by
- 501
- References
- 36
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 43 · 2023: 51 · 2022: 75 · 2021: 61 · 2020: 80 · 2019: 56 · 2018: 49 · 2017: 34 · 2016: 17 · 2015: 4
- FWCI
- 30.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- diabetes mellitus, heart failure hospitalization, cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, heart failure with reduced ejection fraction, risk factors, REACH registry, atherothrombosis, long-term outcomes, comorbidity burden, mortality risk stratification, heart failure with preserved ejection fraction
- MeSH terms
- Aged, Diabetes Mellitus, Female, Follow-Up Studies, Health Status, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Mortality, Prospective Studies, Registries, Thrombosis, Time Factors, Cohort Studies, Treatment Outcome, Internationality, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review